Affiliations: [a] Novartis Global Service Center, Dublin, Ireland
| [b] Novartis Pharma AG, Basel, Switzerland
| [c]
Novartis Healthcare Pvt. Ltd., Hyderabad, India
| [d] Wellmera AG, Basel (at time of research), Switzerland
| [e] IIID Murdoch University, Notre Dame University and Department of Neurology, Fiona Stanley Hospital, Western Australia, Australia
Correspondence:
[*]
Correspondence to: Aoife Callan, PhD, HEOR Manager, Product Lifecycle Services –NBS, Patient Access Services, Novartis Global Service Center, Dublin, Ireland. Tel.: +353 12204901; Mobile: +353 87 098 7652; E-mail: aoife.callan@novartis.com.
Abstract: Background: Sporadic Inclusion Body Myositis (sIBM) is a rare and slowly progressive debilitating muscle disease with symptoms generally developing≥50 years of age. Objective: To conduct a systematic review and meta-analysis of the prevalence of sIBM literature, including a methodological quality assessment of the selected papers. Methods: A systematic search of Medline, Embase, Cochrane Database of Systematic Reviews and major Myositis and Neurological conferences was conducted. Articles reporting prevalence and published in English up to March 2017 were assessed for methodology quality using the Loney quality assessment, Downs & Black score, and the Methodological Evaluation of Observational Research checklists. Meta-analyses using random effects were completed on both general population and≥50 years prevalence estimates. Results: 315 articles were retrieved and data were extracted from 10 relevant studies. One study was subsequently excluded due to methodological issues. The meta-prevalence estimate from 9 papers was 24.8/1,000,000 (95% CI: 20.0–29.6). The methodological quality results were consistent across assessment tools with four articles scoring 4 or 5 out of 8 in the Loney assessment. The meta-prevalence of these four articles was 45.6/ 1,000,000 (95% CI: 35.9–55.2). Conclusion: There was high variability in reported sIBM prevalence estimates and the quality of the studies conducted. Existing evidence suggests an increase of prevalence estimates over time, which may be explained by growing disease awareness, improvements in diagnostic criteria and study methodologies. Further high quality studies are needed to understand if prevalence varies across geographies or ethnicities.
Keywords: Inclusion Body Myositis, epidemiology, prevalence, idiopathic inflammatory myopathies, meta-analysis
